Metformin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Polycystic Ovary Syndrome

• Combined oral contraceptives (various)

Also listed for Type 2 Diabetes Mellitus

• Canagliflozin
• Dapagliflozin
• Dulaglutide
• Empagliflozin
• Glimepiride
• Glipizide
• Insulin Glargine

Other medications in Diabetes & Metabolism

• Naltrexone-Bupropion
• Nateglinide
• Orlistat
• Phentermine
• Phentermine-Topiramate
• Pioglitazone
• Repaglinide
• Saxagliptin

About Metformin

Metformin is a cornerstone medication for managing Type 2 Diabetes, helping millions regulate blood sugar and improve their health. As a member of TheDrugClub, you don't just get access to vital medications like Metformin; you get them at an unbeatable price.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Metformin is approved for (FDA label)

Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: June 15, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Metformin (FDA label)

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (> 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally > 5 mcg/mL [ see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and Precautions (5.1) ] . Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [ see Dosage and Administration (2.2) , Contraindications (4) , Warnings and Precautions (5.1) ]. If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [ see Warnings and Precautions (5.1) ]. WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning. • Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias.

Source: FDA prescribing information (DailyMed). Set ID: 7e41818c-60e9-4bcf-9586-7bb8d33d5e89. SPL document ID: 2a0bac1b-3575-4b62-a74b-07f54ba064af. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Metformin (FDA label)

Metformin Hydrochloride Extended-Release Tablets, USP are available containing 500 mg or 1000 mg of metformin hydrochloride, USP. • The 500 mg tablets are pink, film-coated, round, unscored tablets imprinted with M over MN2 in black ink on one side of the tablet and blank on the other side. • The 1000 mg tablets are pink, film-coated, round, unscored tablets imprinted with M over MN1 in black ink on one side of the tablet and blank on the other side. Extended-Release Tablets: 500 mg and 1000 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7e41818c-60e9-4bcf-9586-7bb8d33d5e89. SPL document ID: 2a0bac1b-3575-4b62-a74b-07f54ba064af. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Metformin (FDA label)

The following adverse reactions are also discussed elsewhere in the labeling: • Lactic Acidosis [ see Boxed Warning and Warnings and Precautions (5.1) ] • Vitamin B 12 Deficiency [ see Warnings and Precautions (5.2) ] • Hypoglycemia [ see Warnings and Precautions (5.3) ] Common adverse reactions are diarrhea, nausea/vomiting, abdominal pain, constipation, abdomen distention, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 7e41818c-60e9-4bcf-9586-7bb8d33d5e89. SPL document ID: 2a0bac1b-3575-4b62-a74b-07f54ba064af. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Metformin (FDA label)

Metformin hydrochloride extended-release tablets are contraindicated in patients with: • Severe renal impairment (eGFR below 30 mL/min/1.73 m 2 ) [ see Warnings and Precautions (5.1) ]. • Hypersensitivity to metformin. • Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. • Severe renal impairment (eGFR below 30 mL/min/1.73 m 2 ) ( 4 , 5.1 ) • Hypersensitivity to metformin ( 4 ) • Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 7e41818c-60e9-4bcf-9586-7bb8d33d5e89. SPL document ID: 2a0bac1b-3575-4b62-a74b-07f54ba064af. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Metformin (FDA label)

• Lactic Acidosis: See boxed warning ( 5.1 ) • Vitamin B 12 Deficiency: Metformin may lower vitamin B 12 levels. Measure hematological parameters annually and vitamin B 12 at 2 to 3 year intervals and manage any abnormalities ( 5.2 ) • Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required ( 5.3 ) 5.1 Lactic Acidosis There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred with severe acidosis.

Source: FDA prescribing information (DailyMed). Set ID: 7e41818c-60e9-4bcf-9586-7bb8d33d5e89. SPL document ID: 2a0bac1b-3575-4b62-a74b-07f54ba064af. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Metformin (FDA label)

Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider more frequent monitoring of these patients. Examples: Topiramate, zonisamide, acetazolamide or dichlorphenamide. Drugs that Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ]. Intervention: Consider the benefits and risks of concomitant use with metformin hydrochloride extended-release tablets.

Source: FDA prescribing information (DailyMed). Set ID: 7e41818c-60e9-4bcf-9586-7bb8d33d5e89. SPL document ID: 2a0bac1b-3575-4b62-a74b-07f54ba064af. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.